Overview

Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

Status:
Recruiting
Trial end date:
2023-06-13
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 once-weekly subcutaneous doses of PB-119 in Drug-naïve T2DM Subjects.
Phase:
Phase 3
Details
Lead Sponsor:
PegBio Co., Ltd.